{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-038129","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.930742+00:00","generated_at":"2026-06-06T00:32:00.725742+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XOMA to acquire Kinnate Biopharma for up to $2.5879 per share plus CVR","bullets":["Cash consideration of $2.3352 base plus up to $0.2527 additional per share; plus CVR for 85% or 100% of program sale proceeds.","Kinnate must have at least $120M net cash at closing; expected close in April 2024.","XOMA expects to add ~$9.5M cash to balance sheet and acquire early-stage oncology programs.","Support agreements covering ~46% of Kinnate shares signed; Kinnate board unanimously approved.","Tender offer to commence by March 4, 2024; financing condition waived."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-038129","json":"https://secwatch.observer/filing/0001193125-24-038129.json","markdown":"https://secwatch.observer/filing/0001193125-24-038129.md","text":"https://secwatch.observer/filing/0001193125-24-038129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524038129/0001193125-24-038129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524038129/d793007d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:32:00.725742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3727bfd7e2adbe1ac5f60c048d585ee5ac7d9ec4","claim":"XOMA Royalty Corp entered into Merger Agreement with Kinnate Biopharma Inc. (effective 2024-02-16).","evidence_excerpt":"On February 16, 2024, XOMA Corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kinnate Biopharma Inc., a Delaware limited liability company (“Kinnate”), and XRA 1 Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524038129/0001193125-24-038129-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Kinnate Biopharma Inc."},{"label":"Effective","value":"2024-02-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}